Ziprasidone: Difference between revisions
Elcatracho (talk | contribs) |
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
||
| Line 45: | Line 45: | ||
*D2 and 5HT2 antagonist. Also strong α-1 blocker, antihistamine-1. | *D2 and 5HT2 antagonist. Also strong α-1 blocker, antihistamine-1. | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ziprasidone]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=broadtable | |||
|headers=plain | |||
|link=subject | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revision as of 16:44, 20 March 2026
Administration
- Type: Atypical antipsychotic
- Dosage Forms:
- Routes of Administration: PO, IM
- Common Trade Names: Geodon
Adult Dosing
- Mania/psychosis: 40 to 80 mg PO BID
- Acute agitation: 10-20mg IM q2-4h, 40mg max daily
Pediatric Dosing
- Age 10-17: slowly titrate up to target dose 20-80mg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- QT prolongation, concomitant administration of other QT prolonging medications
- Decompensated heart failure, recent MI
Adverse Reactions
Serious
- Prolonged QT, torsades de pointes, syncope
- Neuroleptic malignant syndrome, tardive dyskinesia, seizure
- Bone marrow depression
- Dysphagia
- Hyperglycemia, diabetes
- Priapism
Common
- Extrapyramidal disease, dystonia, tremor, akathisia
- Dizziness, asthenia, somnolence, anxiety
- Nausea/vomiting, diarrhea, constipation
- Weight gain
- Rash
- Visual changes
- URI
Pharmacology
- Half-life: 2-7h
- Metabolism: Hepatic: CYP3A4, and CYP1A2
- Excretion: Mostly fecal
Mechanism of Action
- D2 and 5HT2 antagonist. Also strong α-1 blocker, antihistamine-1.
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population | |
|---|---|---|---|---|---|
| Agitated or combative patient#Ziprasidone Atypical antipsychotic for agitation Adult | Agitated or combative patient | 20 mg IM | Atypical antipsychotic for agitation | IM | Adult |